SER Stock Overview
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Serina Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.90 |
| 52 Week High | US$19.93 |
| 52 Week Low | US$8.56 |
| Beta | 0 |
| 1 Month Change | -33.88% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| SER | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.3% | 0.1% | 2.2% |
| 1Y | n/a | -1.0% | 22.8% |
Return vs Industry: Insufficient data to determine how SER performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how SER performed against the US Market.
Price Volatility
| SER volatility | |
|---|---|
| SER Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SER's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SER's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 7 | Steve Ledger | serinatherapeutics.com |
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson’s disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson’s disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology.
Serina Therapeutics, Inc. Fundamentals Summary
| SER fundamental statistics | |
|---|---|
| Market cap | US$77.33m |
| Earnings (TTM) | US$5.27m |
| Revenue (TTM) | US$3.15m |
14.2x
P/E Ratio23.7x
P/S RatioIs SER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SER income statement (TTM) | |
|---|---|
| Revenue | US$3.15m |
| Cost of Revenue | US$2.36m |
| Gross Profit | US$797.57k |
| Other Expenses | -US$4.47m |
| Earnings | US$5.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.63 |
| Gross Margin | 25.29% |
| Net Profit Margin | 167.11% |
| Debt/Equity Ratio | 72.6% |
How did SER perform over the long term?
See historical performance and comparison